Drug Companies

 
Stock Quotes for Drug Companies top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 524689 investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for ankurdrugs investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for pdpl investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for 530317 investment picks
  • Industry: Chemicals
  • Sector: Basic Materials
  • Stock Style: Small Value
Sign-up for 532637 investment picks

 
News Articles for Drug Companies top ^
2014/8/26
Improving Patient Safety and Saving Health Care Dollars: Pharmacists Can Play Key Role in Reducing Drug Therapy Problems Canada NewsWire TORONTO , Aug.
Sign-up for Improving Patient Safety and Saving Health Care Dollars: Pharmacists Can Play Key Role in Reducing Drug Therapy Problems investment picks
By Quentin Fottrell, MarketWatch Amphetamines, painkillers show up in more drug tests -Quentin Fottrell; 415-439-6400; AskNewswires@dowjones.com Amphetamines, painkillers show up in more drug tests -Quentin Fottrell; 415-439-6400; AskNewswires@dowjones.com Though the number of employees testing positive for most illegal drugs is on the decline, those testing positive for amphetamines and some prescription drugs has tripled in the last 10 years.
Sign-up for UPDATE: Abuse of these drugs has tripled among U.S. workers investment picks
By Quentin Fottrell, MarketWatch Amphetamines, painkillers show up in more drug tests -Quentin Fottrell; 415-439-6400; AskNewswires@dowjones.com Amphetamines, painkillers show up in more drug tests -Quentin Fottrell; 415-439-6400; AskNewswires@dowjones.com Though the number of employees testing positive for most illegal drugs is on the decline, those testing positive for amphetamines and some prescription drugs has tripled in the last 10 years.
Sign-up for UPDATE: Abuse of these drugs has tripled among U.S. workers investment picks
Colorado and Washington experience surges in marijuana tests positivity rate, but data suggests state legalization of recreational marijuana may not be sole driver of increases MADISON, N.J. , Sept.
Sign-up for Workforce Drug Test Positivity Rate Increases for the First Time in 10 Years, Driven by Marijuana and Amphetamines, Finds Quest Diagnostics Drug Testing Index™ Analysis of Employment Drug Tests investment picks
~"Mouth" spot encourages teens to speak for themselves NEW YORK , July 17, 2014 /PRNewswire-USNewswire/ -- The Partnership for Drug-Free Kids premiered today a new teen-targeted television spot as part of its Above the Influence (ATI) campaign.
Sign-up for The Partnership for Drug-Free Kids Releases New Teen-Targeted PSA, Driving Teens to Above The Influence Campaign investment picks
Three-year analysis of more than 1.4 million test results also shows majority of Americans continue to put health at risk through dangerous drug combinations and skipping doses MADISON, N.J. , July 16, 2014 /PRNewswire/ -- Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics (NYSE: DGX) , the world's leading provider of diagnostic information services.
Sign-up for Decline in Prescription Drug Misuse More than Twice as High in States with Broad Drug Abuse Prevention Programs, New Quest Diagnostics Health Trends Study Finds investment picks
Potentially expanding its gastrointestinal-focused pipeline, RedHill has secured an option to acquire RP101 from Dresden-based RESprotect GmbH, a spin-off from the Fraunhofer-Society RP101 has completed several Phase I and Phase II clinical studies RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) TEL-AVIV, Israel, Aug.
Sign-up for RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101 investment picks
NATICK, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel, first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has found the effectiveness and safety technical sections complete to support conditional approval under a New Animal Drug Application (NADA) for Karyopharm's novel, oral Selective Inhibitor of Nuclear Transport (SINE) compound Verdinexor (KPT-335) for the treatment of canine lymphoma.
Sign-up for Karyopharm Announces: FDA Considers the Effectiveness and Safety Technical Sections Complete to Support Conditional Approval for the New Animal Drug Application for Verdinexor (KPT-335) to Treat Lymphoma in Client Owned Dogs investment picks
Eagle Pharmaceuticals Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) announced today that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to bendamustine hydrochloride (“HCl”), a ready-to-dilute concentrate solution for injection that will be administered by infusion over 10 minutes after dilution in 50mL of sodium chloride (“saline”) or a saline / dextrose mixture, for the treatment of chronic lymphocytic leukemia (“CLL”) and indolent B-cell non-Hodgkin’s lymphoma (“NHL”). Pursuant to the orphan drug designation, Eagle is eligible to receive tax incentives and Prescription Drug User Fee Act (“PDUFA”) fee savings, and believes it may receive seven years of marketing exclusivity.
Sign-up for Eagle Pharmaceuticals Receives Orphan Drug Designation for Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product for Chronic Lymphocytic Leukemia and Indolent B-Cell Non-Hodgkin’s Lymphoma investment picks
2014/8/21
Manulife and Bayshore Healthcare Ltd.
Sign-up for Manulife and Bayshore Healthcare Ltd. to Introduce a Preferred Provider Network to Manage Specialty Drugs investment picks
LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that Roche has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a multicenter, Phase 2 clinical study of Erivedge ® (vismodegib) in patients with idiopathic pulmonary fibrosis (IPF), a chronic, debilitating lung disease.
Sign-up for Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis investment picks
BELLEVILLE, ON , July 29, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, an application for Orphan Drug Designation for its Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory/relapsing high grade non-muscle invasive bladder cancer.
Sign-up for Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECO ® in people with cystic fibrosis (CF) ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR) gene.
Sign-up for Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation investment picks
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for its investigational antibiotic ceftolozane/tazobactam with Priority Review.
Sign-up for Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review investment picks
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Drug Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Driving Sales  |  Next: Drug Delivery Shares